ORAGENICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ORAGENICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 29, 2019 |
| FY2018 | Sep 30, 2018 | $0 | Mar 29, 2019 |
| FY2018 | Jun 30, 2018 | $0 | Mar 29, 2019 |
| FY2018 | Mar 31, 2018 | $0 | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Mar 29, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Mar 29, 2019 |
| FY2018 | Jun 30, 2017 | $0 | Mar 29, 2019 |
| FY2018 | Mar 31, 2017 | $0 | Mar 29, 2019 |
| FY2015 | Dec 31, 2015 | $240.2K | Mar 30, 2016 |
| FY2015 | Sep 30, 2015 | $329.8K | Mar 30, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $37.7K | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $131.5K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $87.0K | Apr 17, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Feb 16, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Feb 16, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Feb 16, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Feb 16, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Feb 16, 2018 |
| FY2017 | Jun 30, 2016 | $0 | Feb 16, 2018 |
| FY2017 | Mar 31, 2016 | $0 | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | $0 | Feb 27, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Feb 27, 2017 |
| FY2015 | Dec 31, 2014 | $570.3K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $688.9K | Feb 27, 2015 |
| FY2013 | Dec 31, 2012 | $453.3K | Feb 28, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.84M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($10.57M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($20.66M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($14.29M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($15.71M) | Apr 17, 2023 |
| FY2020 | Dec 31, 2020 | ($4.41M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($4.50M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($12.34M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($5.19M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($3.60M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.36M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($10.56M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($20.90M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($14.42M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($15.77M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($26.64M) | Jul 29, 2022 |
| FY2020 | Dec 31, 2019 | ($15.88M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($9.99M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($6.72M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($8.54M) | Feb 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.39M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $4.11M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $15.49M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $10.07M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $10.59M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $22.11M | Jul 29, 2022 |
| FY2020 | Dec 31, 2019 | $12.12M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $5.97M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $3.54M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.75M | Feb 16, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $3.54M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $3.32M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $7.54M | Feb 27, 2015 |
| FY2013 | Dec 31, 2012 | $5.02M | Feb 28, 2014 |
| FY2012 | Dec 31, 2011 | $5.63M | Mar 26, 2013 |
| FY2011 | Dec 31, 2010 | $6.29M | Apr 16, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.25M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($8.60M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($7.29M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($15.23M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($13.47M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($16.95M) | Jul 29, 2022 |
| FY2020 | Dec 31, 2019 | ($13.01M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($9.08M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($6.36M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($7.08M) | Feb 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $127.5K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $43.9K | Apr 17, 2023 |
| FY2020 | Dec 31, 2019 | $25.2K | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $124.7K | Mar 4, 2020 |
| FY2017 | Dec 31, 2016 | $27.2K | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $102.5K | Feb 27, 2017 |
| FY2015 | Dec 31, 2014 | $110.7K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $18.8K | Feb 27, 2015 |
| FY2013 | Dec 31, 2012 | $11.1K | Feb 28, 2014 |
| FY2011 | Dec 31, 2010 | $88.1K | Apr 16, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.07M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.47M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $4.97M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $14.76M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $28.23M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $18.68M | Jul 29, 2022 |
| FY2020 | Dec 31, 2019 | $19.75M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $22.05M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $7.21M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.31M | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.68M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.80M | Mar 14, 2025 |
| FY2011 | Dec 31, 2011 | $9.45M | Apr 16, 2012 |
| FY2011 | Dec 31, 2010 | $3.63M | Apr 16, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.28M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($211.9K) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $3.17M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $13.01M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $26.49M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $16.84M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $17.23M | Jul 29, 2022 |
| FY2020 | Dec 31, 2018 | $20.88M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $6.32M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $2.97M | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($226.63M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($216.79M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($206.22M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($185.56M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($171.27M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($154.44M) | Jul 29, 2022 |
| FY2020 | Dec 31, 2019 | ($127.35M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($111.37M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($101.40M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($94.67M) | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.40M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $864.8K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $3.48M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $11.43M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $27.27M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $17.64M | Jul 29, 2022 |
| FY2020 | Dec 31, 2019 | $18.27M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $20.21M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $6.17M | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $4.08M | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (47) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Jul 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (47) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Mar 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.27M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 419,003 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 3.08M | Mar 14, 2025 |
| FY2023 | Jan 23, 2023 | 2.00M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | 2.02M | Mar 29, 2024 |
| FY2023 | Dec 23, 2022 | 117.00M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 2.00M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 91.77M | Jul 29, 2022 |
| FY2020 | Dec 31, 2019 | 46.12M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 29.43M | Mar 4, 2020 |